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ABSTRACT
Introduction: In the last two decades, there has been strong evidence supporting
the use of noninvasive ventilation (NIV) in COPD cases. While there are advocates in
favor of the use of NIV in patients presented with acute hypoxemic respiratory failure
(AHRF) non-related to COPD nor chest trauma, efficacy of NIV in these cases is still
heatedly debated in the medical research field.
Objective: To critically assess the existing scientific evidence regarding efficacy
of NIV as an adjunct therapy, the endotracheal intubation rate, intensive care and hospital
length of stay, fatal complications, and mortality rate in patients presented with AHRF in
non-COPD, non-trauma situations.
Data Source: A search of PubMed, MEDLINE database from 1990 to 2010,
Cochrane Library, and EMBASE from 1990 to 2010 were also conducted.
Study Selection: Randomized controlled trials (n=11) that assessed the efficacy of
NIV in patient with AHRF not related to COPD nor trauma, in addition to various cohort
studies, observational studies, and some selective conference proceedings that are
considered potentially relevant to the topic.
Results: The use of NIV showed a statistically significant decrease in intubation
and mortality rates in patients with immunosuppression who developed AHRF. There
were also encouraging results in patients who underwent lung resection, and postabdominal surgical procedures who received NIV to treat AHRF.
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Conclusion: This systematic review of a number of RCTs suggests that the use of
NIV decreases the need for endotracheal intubation, fatal complications, and mortality
rate. However, due to the diversity of study population, there is a great need for more
specific trials on less heterogeneous patients with AHRF.
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CHAPTER Ι: BACKGROUND
What Is Acute Hypoxemic Respiratory Failure?
Acute hypoxemic respiratory failure (AHRF) is severe arterial hypoxemia (low
oxygenation in arterial blood) that does not respond to supplemental oxygen provided. It
is caused by intrapulmonary shunting of blood (i.e. the availability of perfusion without
ventilation) secondary to collapsed or fluid-filling air sacs (alveoli). Symptoms include
dyspnea (shortness of breath) and tachypnea (abnormally rapid breathing). AHRF can be
diagnosed by obtaining arterial blood gas samples (ABG) and chest radiography.
Treatment usually requires mechanical ventilation whether invasive or noninvasive
(Beers, Porter, Jones, Kaplan, & Berkwits, 2006).
Noninvasive ventilation (NIV) is the delivery of mechanical ventilation without
using an invasive artificial airway for the management of acute respiratory failure caused
by various etiologies.

Historical Overview
NIV was first introduced in the early 20th century in the form of negative pressure
ventilation in which a patient is placed in a large metal cylinder (iron lung), which
encases the patient, who lay on his/her back on a mattress with the head protruding
through an air-tight rubber neck seal (see Figure 1). It was widely used during the polio
epidemics in the 1900s. The bulk and lack of portability of early tank ventilators
stimulated the development of more portable negative pressure devices, including the
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chest cuirass (see Figure 2) or “shell” ventilator and raincoat (or wrap) ventilator. The
first cuirass, developed in 1876 by Ignez von Hauke in Austria, consisted of an iron shell
covering the anterior part of the thorax with an air-filled rubber edge that created a tight
seal around the chest (Mehta & Hill, 2001).

Figure 1. “Iron Lung” is a well-known negative pressure ventilator. Retrieved from:
http://colgurchemistry.com/Science9/Biology/iron%20lung%202.jpg

Figure 2. “Chest Cuirass” is another type of negative pressure ventilator. Retrieved from
United Hayek: http://nivusers.tripod.com/psfolder/Hayek2.jpg

Prior to 1950, invasive positive pressure ventilation was exclusively used for the
delivery of anesthesia during surgical procedures. However, in 1952 in Copenhagen,
Denmark, and during the peak outbreak of the polio epidemic, and due to the
overwhelming number of patients who required mechanical ventilation, there was a
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massive shortage of negative pressure machines. At that point, positive pressure
ventilation was first deployed to treat patients outside the anesthesia departments and the
survival rates were much better with the positive pressure ventilation than with the
negative pressure ventilation. That success during the difficult epidemic caused clinicians
to switch to invasive positive pressure ventilation supported by the first use of intensive
care units (ICUs) and by the less expensive, and user-friendly ventilators. Invasive
ventilation delivered via endotracheal tube then became the first choice method to
provide mechanical ventilation to patients with acute respiratory insufficiency (Mehta &
Hill, 2001).

Reemergence of Noninvasive Ventilation
Because of the major complications associated with the use of invasive positive
pressure ventilation, the practice of using NIV has increased to avoid such complications.
Although invasive positive pressure ventilation is practically reliable in ensuring effective
alveolar ventilation, endotracheal intubation involves serious risks of adverse
complications: during the process of insertion or removal of the endotracheal tube; during
the ventilation application such as barotrauma (i.e., airway injury due to excessive
pressure); or those caused by the accidental loss of artificial airways; the bypassing of the
patient’s natural upper airway filtering and humidification mechanisms (Pingleton, 1988).
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Types of Noninvasive Ventilation
NIV comes in two forms, noninvasive positive pressure ventilation (NIPPV) and
continuous positive airway pressure (CPAP). NIPPV is a combination of inspiratory
pressure support (also known as inspiratory positive airway pressure [IPAP]) plus
positive end expiratory pressure (PEEP) (also known as expiratory positive airway
pressure [EPAP]) delivered to the patient via a mask interface. Biphasic positive airway
pressure (BiPAP1) (Respironics, Murrayville, PA) (see Figures 3 and 4), Bilevel, and
noninvasive pressure support ventilation (NIPSV) are also used to describe NIPPV.
CPAP provides a baseline constant positive airway pressure throughout inspiration and
expiration, whereas BIPAP provides two levels of pressure: IPAP during inspiration and
EPAP during expiration phase.

Figure 3. Nasal NIV Mask. Retrieved from:
www.aic.cuhk.edu.hk/web8/NIV%20masks.htm
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Figure 4. Respironics Bipap-Vision with full face mask. Retrieved from
Respironics.com: www.healthcare.philips.com/main/products/Hospital_
Respiratory/Products/Noninvasive_ventilation/respironics_bipap_vision.wpd

Golden Age of Noninvasive Ventilation
Over the last two decades, there has been tremendous development in the field of
NIV. In the 1980s, CPAP was delivered via face mask to treat sleep apnea. Later, volume
and pressure-control were used to treat cases of chest wall deformity diseases,
neuromuscular respiratory disorders, and acute respiratory failure (ARF) (Benditt, 2009).
The implementation of noninvasive positive pressure ventilation (NIV) as a firstline treatment in selected cases of acute respiratory failure is considered the single most
important progress in the field of mechanical ventilation in the past two decades. In this
review, NIV will be defined as the application of NIV, most commonly in the form of
BiPAP, which provides pressure support in addition to positive end expiratory pressure
(PEEP), and the other form is continuous positive airway pressure (CPAP), which is the
equivalence of PEEP alone. It differs from BiPAP by having no added ventilatory support
during the inspiratory cycle (Elliott, Steven, Phillips, & Branthwaite, 1990; Meduri et al.,
1991).
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CHAPTER ΙΙ: INTRODUCTION
Strong evidence involving several randomized controlled trials (RCTs) supports
the use of NIV as an adjunct to standard therapy for the management of acute
exacerbation of chronic obstructive pulmonary disease (COPD) particularly when used in
early phases of the disease (Keenan, Powers, McCormack et al., 2002; Ram, Picot,
Lightowler, & Wedzicha, 2004). However, evidence supporting the efficacy of NIV in
patients with hypoxemic respiratory failure due to causes other than COPD is still
debated and has produced conflicting results (Hill, Brennan, Garpestad, & Nava, 2007).
The aim of this study is to conduct a systematic review of RCTs in the medical
literature of patients with AHRF unrelated to exacerbation of COPD and chest trauma to
assess the efficacy of NIV when combined with the usual medical care (UMC) as
compared to the UMC alone. The main outcome measures are endotracheal intubation,
ICU and hospital length of stay, complications, and mortality rate.
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CHAPTER ΙΙΙ: METHOD & PROCEDURES
Search Strategy
A search of PubMed using the terms “non-invasive ventilation”, “noninvasive
ventilation”, “non-invasive positive pressure ventilation”, “BiPAP”, and “CPAP” was
conducted. Literature searches on NIV in MEDLINE from 1990 to 2010, Cochrane
database, EMBASE from 1990 to 2010 were also conducted. In this review, the focus is
limited to RCTs only (see Figure 4), and included other articles in the background and the
introduction. All of the RCTs are available in full texts using the Albertson Library,
Boise State University website (http://library.boisestate.edu/).

Selection Criteria
The following criteria were used to select articles:
1. Study design was a randomized controlled trial.
2. Study population consisted of a majority of patients (>60%) with acute
hypoxemic respiratory failure not associated with an exacerbation of COPD
and not requiring immediate ventilatory assistance.
3. The intervention included noninvasive ventilation (NIV) plus usual medical
care (UMC) vs. UMC alone.
4. Outcomes included the need for endotracheal intubation, length of ICU or
hospital stay, or ICU and/or hospital mortality.
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Study Selection
Initial electronic searches identified 315 studies as potentially relevant to the
topic. Of these, studies were excluded for the following reasons:
1. They were not randomized controlled trials or did not evaluate noninvasive
ventilation (n = 232).
2. The patients did not have acute hypoxemic respiratory failure or the study
population was mixed and patients with acute hypoxemic respiratory failure
were not reported separately (n = 72).
The remainder, a total of eleven randomized controlled trials, all fully published,
met the set selection criteria (see Figure 5, Table1).
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315 studies were
identified as potentially
relevant to the topic.
(232) trials were excluded as
not relevant or as not
controlled trials.
(83) Trials were retrieved
for more detailed
evaluation.

(11) Trials were included in
the review.
Number of trials with
respect to Outcomes used:
Endotracheal intubation (11)
Complications (7)
ICU Length of Stay (9)
Hospital Length of Stay (8)
Mortality (11)

(72) Trials were excluded
because:
Non-hypoxemic respiratory
failure (63), Used different
outcomes that didn’t meet
criteria (9).

Figure 5. Flow diagram of trial selection process for this systematic review
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Table 1.
RCTs Included in this Review
Study, year
(No. of
Participants)
1-Wysocki et
al., 1995
(n=41)

Age
(Yrs)

Gender
M/F

Disease

Sample
size

NIV=64±18
UMC=
62±11

NIV= 12/9
UMC=12/8

ARF (no COPD)
PaCO2>45 (n=17)
PaCO2≤45 (n=24)

NIV=21
UMC=20

2- Confalonieri
et al., 1999
(n=56)

NIV=66±14
UMC=
61±21

CAP+ARF (n=23),
AHRF (n=33)*

NIV=28
UMC=28

yes

3- Antonelli et
al., 2000.
(n=40)

NIV=45
UMC=
44

ARF solid organ
transplantation

NIV=20
UMC=20

yes

4- Delclaux et
al., 2000.
(n=123)

NIV=
62
UMC=
61
NIV=58.9±10
UMC=
63±9
NIV=48±14
UMC=
50±12

NIV=
23/5
UMC=
17/11
NIV;
13/7
UMC=
12/8
NIV=
38/24
UMC=
40/21
NR

ALI/ARDS

NIV=62
UMC=61

yes

AHRF post-lung
resection

NIV=24
UMC=24

yes

NIV=
18/8
UMC=
19/7

AHRFimmunosuppressed

NIV=26
UMC=26

yes

NR

ARF, postextubation AHRF

NIV=39
UMC=42

yes

5-Auriant et al.,
2001. (n=48)
6-Hilbert et al.,
2001. (n=52)

7-Keenan et al.,
2002. (n=81).

NIV=68.3
(13.1)
UMC=
68.6
(12.4)

Informed
Consents
Obtained
yes

Table 1 continues

21
Table 1 (continued)
Study, year
(No. of
Participants)
8- Ferrer et al.,
2003. (n=105)

Age
(Yrs)

Gender
M/F

Disease

Sample
size

NIV=61±17
UMC=
62±18

NIV=
30/32
UMC =
28/26

AHRF

NIV=51
UMC=54

9-L’Her et al.,
2004. (n=89)

NIV=
84±6
UMC=
84±6
NIV=
65(10)
UMC=
66(9)
NIV=
77±10
UMC=
79±9

NIV=
18/28
UMC =
19/24
NIV=
71/34
UMC =
64/40
NIV=
393/309
UMC=
213/154

ACPE Elderly
(>75 yrs old

NIV=43
UMC=46

yes

AHRF Postoperative

NIV=105
UMC=104

yes

ACPE

NIV=702
UMC=367

yes

10-Squadrone
et al.,
2005. (n=209)
11-Gray et al.,
2008. (n=1069)

Informed
Consents
Obtained
yes

NIV: noninvasive ventilation; UMC: usual medical care; ARF: acute respiratory failure;
AHRF: acute hypoxemic respiratory failure; CAP: community acquired pneumonia;
ACPE: acute cardiogenic pulmonary edema; ALI: acute lung injury.
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CHAPTER IV: RESULTS
Study Description
Studies included in this review involve an international experience, as they
included data from five different countries (France 1, 4, 5, 6 & 9; Italy 2, 3 & 10; Spain
8; Canada 7; and the United Kingdom 11). Five studies involved multiple center trials (2,
4, 8, 10 & 11). Patient populations with hypoxemic respiratory failure enrolled in these
11 RCTs were diverse. Two trials focused on immunocompromised patients (3, 6), two
on acute cardiogenic pulmonary edema (ACPE) patients (9, 11), one on post-lung
resection surgery patients (5), one on community-acquired pneumonia (CAP) (2), one on
post-extubation respiratory failure (7), one on acute lung injury (ALI) (4), one study on
post-abdominal surgery (10), and two on more heterogeneous groups of patients (1, 8)
(see Table 1).

Study Results
Wysocki et al. Total of 41 patients with non-COPD ARF were included in this
RCT between July 1990 and October 1992. Twenty were randomly assigned for UMC,
and twenty one were assigned for NIV treatment. Fourteen of the 20 patients (70%) who
received UMC alone were endotracheal intubated versus 13 of the 21 patients (62%) who
were treated with NIV in addition to UMC (P=0.88) (Table 2). The ICU length of stay
was 25 ± 23 days in the case of UMC patients and 17 ± 19 days in the case of NIV
patients (P=0.16). In the UMC group, 10 of the 20 patients (50%) died, and in the NIV
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group, 7 of the 21 (33%) patients died (P=0.46) (Table 2). In this study population, the
authors performed a subgroup analysis between those patients who had hypercapnea
PaCO2> 45 mm Hg, and the second subgroup that had their PaCO2≤45 mm Hg.
Endotracheal intubation was required in all 6 hypercapnic patients (100%) who received
UMC, while only 4 of the 11 hypercapnic patients (36%) required intubation in the NIV
group (P=0.02). The ICU length of stay was significantly lower in hypercapnic patients
treated with NIV (13 ± 15 days versus 32 ± 30 days, P=0.04) and 4 of the 6 hypercapnic
patients from UMC group died (66%), while one of the 11 hypercapnic patients (9%)
died who received the NIV (P=0.06). Oppositely, in the subgroup of patients with
PaCO2≤ 45 mm Hg (n=24), there were no positive effects with the use of NIV (Table 2).
Confalonier et al. The study took place between November 1996 and March
1998 and included 56 patients with community-acquired pneumonia (CAP) and ARF
from multi-center settings. The population was divided equally, 28 to be treated with
UMC alone and 28 with NIV intervention. Twenty-three patients had a history COPD
and they were analyzed separately. The other non-COPD patients (n=33) were also
analyzed separately, which is the group considered in the analysis. In the UMC group, 8
of the 17 patients (47.1%) required endotracheal intubation while 6 of the 16 patients
(37.5%) in the NIV group required intubation (P=0.73). In the UMC group, the ICU
length of stay was 4.8±1.7 days versus 2.9±1.8 days in the NIV group (P=0.44). The
overall hospital stay was 15.1±2.8 days in the UMC group versus 17.9±2.9 days in the
NIV group (0.48). In the UMC group, 4 of the 17 patients (23.5%) died versus 6 of 16
patients (37.5%) in the NIV group (P=0.47) (Table 2).
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Antonelli et al. The study was conducted between December 1995 and October
1997 and involved 40 patients who received a solid organ transplant (liver, kidney, or
lung) and were treated in ICU for AHRF, which occurred post transplantation. There
were 20 patients randomly assigned in each group. Fourteen patients (70%) in the UMC
group required intubation and 4 patients (20%) in the NIV group (P = 0.002). The length
of stay among the survivors in the ICU was better in the NIV group (5.5 days versus 9
days in the UMC group; (P=0.03)). The mortality rate in the ICU was 10 patients (50%)
in the UMC group versus 4 patients (20%) in the NIV group (P=0.05). Finally, serious
fatal complications leading to death were significantly higher in the UMC group than the
NIV group (10 vs 4; P= 0.05) (Table 2).
Delclaux et al. Between September 1997 and January 1999, 123 adult patients
admitted with acute respiratory insufficiency secondary to pulmonary edema were
recruited at the medical ICUs of 6 hospitals from France, Spain, Tunisia, and Italy. One
hundred and two (83%) patients were presented with acute lung injury (ALI) (PaO2/FIO2
ratio ≤ 300 mm Hg), while 21(17%) were classified as having pure cardiac
decompensation. Patients with an underlying cardiac disease were equally distributed
between the UMC and the CPAP groups. There were 61 patients in the UMC group
versus 60 patients in the CPAP plus UMC group. No significant differences were found
between the two treatment groups for any of the clinical outcome measures studied,
including rate of endotracheal intubation, length of hospital stay, and hospital mortality
rate. However, the complications were more common in the CPAP group: 18 (29%)
versus 6 (10%) in the UMC group (P = 0.01) (Table 2).
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Auriant et al. Between May 1999 and July 2000, 48 patients with AHRF
following lung resection were enrolled in this RCT. The indication for lung resection was
lung cancer for all patients in this population. All the patients were extubated in the
operating room after surgery. The study population was randomly assigned to UMC
alone (n=24) and NIV plus UMC (n=24). In the UMC alone group, 12 of the 24 patients
(50%) required intubation versus only five of the 24 patients (20.8%) in the NIV group (P
=0.035) (Table 2). Nine patients in the UMC group (37.5%) died, versus only three
(12.5%) in the NIV group (P=0.045).The ICU and hospital length of stay were similar in
the two groups. There was no death in either group after hospital discharge, so that in
both groups, in-hospital mortality was equal to 120-d mortality (Table 2).
Hilbert et al. The study took place between May 1, 1998 and December 31, 1999.
A total of 52 patients with immunosuppression were admitted to the ICU with AHRF
associated with pulmonary infiltrates and fever. There were 26 patients in the UMC
group and 26 in the NIV group. Twenty patients of the 26 (77%) in the UMC group
required endotracheal intubation versus 12 patients of the 26 (46%) in the NIV group
(P=0.03). In the UMC group, 18 of the 26 (69%) died in the ICU versus 10 of the 26
(38%) in the NIV group (P= 0.03). The ICU length of stay among survivors was 9±4 days
in the UMC group versus 7±3 days in the NIV group. In the UMC group, hospital
mortality was 21 of the 26 (81%) versus 13 of the 26 (50%) in the NIV group (P= 0.02)
(see Table 2).
Keenan et al. The study was conducted between August 1, 1996 and October 31,
1999. Eighty-one patients who required ventilator support for more than 48 hours, or had
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a history of either congestive heart failure or chronic lung disease, and developed
respiratory distress were randomly assigned to this study (42 patients in the UMC group
and 39 patients in the NIV group). There was no statistically significant difference in the
reintubation rate between the UMC group and the NIV group. In the UMC group, 29 of
the 42 (69%) patients required reintubation versus 28 of the 39 (72%) patients in the NIV
group (P=0.79). The ICU length of stay was 19.4 days in the UMC group and 15.1 days
in the NIV group (P=0.32). The UMC group had 29.8 days hospital stay, whereas the
NIV group had 32.2 days (P=0.69). Both groups had the same mortality rate: 29 of the 42
(69%) in the UMC died versus 27 of the 39 in the NIV group (69%) (P=0.99) (Table 2).
Ferrer et al. This study involved 105 patients from three different ICUs
diagnosed with severe AHRF, defined as a PaO2 less than 60 mm Hg for more than 6-8
hours or arterial oxygen saturation via pulse oximetry (SpO2) persistently below 90%
while breathing 50% FIO2 via Venturi mask. They were randomly assigned to both
groups: 54 in the UMC group and 51 in the NIV group. In those who received the UMC
alone, 28 of the 54 (52%) required endotracheal intubation while only 13 of 51 (25%)
needed intubation in those who were treated with adjunct NIV (P=0.01). In the UMC
group, 17 patients of the 54 (31%) developed septic shock versus 6 patients of the 51
(12%) in the NIV group (P=0.02). In the ICU, 21 patients of the 54 (39%) died in the
UMC group versus 9 patients of the 51 (18%) in the NIV group (P=0.28) (Table 2).
L’Her et al. The study was conducted in three different emergency departments
(EDs) and involved a total of 89 elderly patients (≥ 75 years) admitted to EDs with
AHRF related to cardiogenic pulmonary edema (CPE). The population was randomly
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assigned to receive UMC (n=46) or NIV, particularly CPAP therapy. In the UMC group,
14 of the 46 (30%) required intubation versus 4 patients (9%) in the NIV group. There
were 17 (37%) patients who experienced serious complications in the UMC group versus
4 (9%) in the NIV group. Early 48-hour mortality was significantly lower in the NIV
group; 3 of the 43 (7%) patients died versus 11 of the 46 (24%) in the UMC group
(P=0.017). In-hospital length of stay was 9±7 days in the UMC group versus 12±11 days
in the NIV group (P=0.07) (Table 2).
Squadrone et al. The study took place between June 2002 and November 2003 in
multi-center ICUs. A total of 209 patients were randomly assigned to the study if they
had AHRF post-elective abdominal surgery, with an arterial oxygen tension to inspiratory
oxygen fraction (PaO2/FiO2) ≤ 300 while breathing 50% oxygen via Venturi mask, and
had no underlying cardiac or chronic lung diseases. There were 104 patients in the UMC
group and 105 patients in the NIV group (which used CPAP in this study). The rate of
intubation was lower in the NIV group; only one patient (1%) of the 105 patients required
intubation versus 10 patients (10%) in the UMC group (P=0.005). The ICU length of stay
was 2.6 days in the UMC group versus 1.4 days in the NIV group (P=0.09). Hospital
length of stay was almost similar in the two groups. Serious complications were
significantly less in the NIV group: only 2 (2%) of the 105 patients in the NIV group
developed pneumonia versus 10 (10%) of the 104 patients in the UMC group
(P=0.02).There were no deaths (0%) among the NIV group while three (3%) patients died
in UMC group (P=0.12) (Table 2).
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Gray et al. This is a multi-center study conducted in 26 emergency departments
in district and regional hospitals in the United Kingdom between July 2003 and April
2007. A total of 1069 patients were assigned to a UMC group (367 patients), and 702
patients to a NIV group. There was no significant difference in one week or one month
mortality between patients receiving the UMC and those undergoing the NIV. The
mortality rate for one week was 9.8% in the UMC group and 9.5% in the NIV group (P =
0.87). The mortality rate for one month was 16.4% in the UMC group and 15.2% in the
NIV group (P = 0.64) (Table 2).
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Table 2.
RCTs Results
Study, year

ETI & MV

ICU LOS (days)

Hosp.

Complications

Mortality (%)

(No. of

(%)

UMC vs. NIV

LOS

UMC vs. NIV

UMC vs. NIV

Participants)

UMC vs.

(days)

NIV

UMC vs.
NIV

14(70) vs
13(62) p=
0.88
PaCO2>45: 6
(100) vs 4
(36) p=0.02
PaCO2≤ 45:
8 (57) vs 9
(90) p=0.19

25±23 vs17±19 p=0.16
PaCO2>32±30vs13+ 15
p=0.04
PaCO2≤ 45; 22 ±20 vs
22 ± 22
P = 0.83

NR

NR

10 (50)vs 7(33)
P=0.46
PaCO2>45:4(66)vs
1(9) p=0.06
PaCO2≤45:
6(43) vs 6 (60)
P = 0.76

2- Confalonieri
et al., 1999
(n=56)
AHRF (n=33)
considered

8 (47.1) vs 6
(37.5)
P = 0.73

4.8±1.7
vs
2.9±1.8
P=0.44

15.1±2.8
vs
17.9±2.9
P= 0.48

NR

4(23.5) vs 6(37.5)
P=0.17

3- Antonelli et
al., 2000. (n=40)

14(70) vs
4(20)
P= 0.002

9 vs 5.5
P=0.03

NR

10(50) vs 4(20)
P= 0.05

10(50) vs 4(20)
P= 0.05 icu
11(55) vs 7(35)
P= 0.17hosp

4- Delclaux et
al., 2000.
(n=123)

24(39) vs
21(34)
P=0.53

12 vs 15
P=0.43

32 vs
30.5
P=0.77

6(10) vs 18(29)
P= 0.01 ↑

18(29) vs 19(31)
P= 0.24

5-Auriant et al.,
2001. (n=48)

12(50) vs
5(20.8)
P=0.035

14 vs 16.65
P= 0.52

22.8 vs
27.1
P= 0.61

NR

9(37.5) vs 3(12.5)
P=0.045

6-Hilbert et al.,
2001. (n=52)

20(77) vs
12(46)
P= 0.03

10±4 vs 7±3
P=0.06

NR

21(81) vs 13(50)
P=0.02

21(81) vs 13(50)
P= 0.02

1-Wysocki et
al.,1995 (n=41)
PaCO2>45
(n=17)
PaCO2≤45
(n=24)

Table continues
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Table 2 (continued)
Study, year

ETI & MV

ICU LOS (days)

Hosp.

Complications

Mortality (%)

(No. of

(%)

UMC vs. NIV

LOS

UMC vs. NIV

UMC vs. NIV

Participants)

UMC vs.

(days)

NIV

UMC vs.

17 (40) vs 16

29(69) vs 27(69)
P=0.99

NIV
7-Keenan et al.,
2002. (n=81).

29(69) vs
28(72)
P= 0.79

19.4 vs 15.1
P= 0.32

29.8 vs
32.2
P= 0.69

(41)
P = 0.61

8- Ferrer et al.,
2003. (n=105)

28(52) vs
13(25)
P= 0.01

11.3 vs 9.6
P=0.51

26.8 vs
20.7
P=0.09

17(31) vs 6(12)
P= 0.028

21(39) vs 9(18)
P= 0.028

9-L’Her et al.,
2004. (n=89)

14(30) vs
4(9)
P=0.01

NR

9 vs 12
P=0.07

17(37) vs 4(9)
P=0.002

14(30) vs 12(28)
P= 0.8

10-Squadrone et
al.,
2005. (n=209)

10(10) vs
1(1)
P= 0.005

2.6 vs 1.4
P=0.09

17 vs 15
P=0.10

10(10) vs 1(2)
P= 0.02

3(3) vs 0(0)
P =0.12

11-Gray et al.,

10(2.8) vs
20(2.9)
P=0.9

NR

39(10.5)
vs
77(11.4)
P=0.10

148(40.5) vs
317(45.2)
P= 0.15

60(16.4) vs 107(15.2)
P= 0.64

2008. (n=1069)

ETI & MV: endotracheal intubation and mechanical ventilation; ICU: intensive care unit;
LOS: length of stay; UMC: usual medical care; NIV: noninvasive ventilation; ARF: acute
respiratory failure; CAP: cardiogenic pulmonary edema; AHRF: acute hypoxemic
respiratory failure; ALI: acute lung injury; ACPE: acute cardiogenic pulmonary edema;
NR: not recorded.
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CHAPTER V: ANALYSIS
The results of this systematic review of the RCTs suggest that the early
application of NIV therapy in patients presented with acute hypoxemic respiratory failure
decreases the likelihood of endotracheal intubation. By avoiding the endotracheal
intubation, there is great potential in improving patient outcome. There is a reduction
trend in the rate of endotracheal intubation, ICU length of stay, and ICU mortality in
these RCTs (see Table 3). These results were consistent when patients with COPD were
excluded.

Immunosuppressed Patients with AHRF
Two of the studies in which immunosuppressed patients with AHRF who
received NIV showed statistically significant results in terms of need of endotracheal
intubation, rate of complications, and, most importantly, decreased mortality rates
(Antonelli et al., 2000; Hilbert et al., 2001) (see Table 3, Figure 6). The success of the
NIV in such cases was probably a result of the avoidance of complications associated
with the invasive mechanical ventilation in those vulnerable populations (Hill, 2001).
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Acute Lung Injury/Acute Respiratory Distress Syndrome (ALI/ARDS)
A study conducted on patients with ALI revealed no benefits from adding CPAP
to the UMC in those types of cases. In addition, there were more patients from the CPAP
group who developed significantly higher rates of adverse events (Declaux et al., 2000)
(see Table 3, Figure 7). This could be due to the delay of conventional mechanical
ventilation these patients needed to improve ventilation rather than oxygenation alone. In
a similar population, a multi-center cohort study was conducted on a total of 299 patients
at 70 ICUs. All patients were labeled as having ALI/ARDS after excluding those who
had COPD or CPE. Of those, 209 (70%) were intubated directly without undergoing a
NIV trial. The remainder 90 (30%) patients underwent NIV as a first-line therapy. Fiftyfour (60%) patients in the NIV group required intubation. The overall ICU mortality was
40% in the NIV group. However, the authors concluded that although the successful NIV
trial had a lower mortality rate, the group who failed the NIV trial had a much higher
mortality rate than those who were intubated initially without undergoing NIV trials
(Demoule et al., 2006a & 2006b). Another cohort study conducted on patients with
ALI/ARDS used PS+ PEEP as NIV with limited tidal volume (VT of 6 ml/kg) and
adjusted the PS and PEEP according to the patient’s need. They managed to avoid
intubation in 54% of the NIV patients. There was a statistical significance in the ICU
mortality rate between those who avoided intubation (6%), as compared to those who
failed the NIV trial (53%). Hospital mortality was also significantly lower in those who
avoided intubation (19%) as compared to 54% in the NIV failures (Antonelli et al., 2007)
(Table 3).

33
Post-Extubation AHRF
Keenan and colleagues conducted a study on 81 post-extubation patients who
developed AHRF within 48 hours post-extubation, which showed no advantages from the
use of the NIV therapy (see Table 3, Figure 8). In addition, another RCT, which is not
included in this review, involved 224 patients from various medical centers and went
further into this issue: it showed that the mortality rate was higher in the NIV group than
in the UMC group (25% versus 14%, P = 0.048) (Esteban et al., 2004).

Community-Acquired Pneumonia
The use of the NIV did not result in significant benefits in patients who were
presented with CAP and developed AHRF and had no underlying COPD disease
(Confalonieri, Potena, & Carbone et al., 1999) (see Figure 9). However, the same author
in a non-randomized clinical trial of AIDS patients presented with severe pneumocystis
pneumonia and managed by NIV showed improvement in their outcomes as compared to
the group who received invasive mechanical ventilation (Confalonieri, Calderini, &
Terraciano, et al., 2002). Interestingly enough, in a RCT that involved 105 patients
presented with AHRF from heterogeneous causes, the authors indicated a significantly
lower intubation rate and death rate in a subgroup of 34 patients with pneumonia treated
with NIV as compared to the UMC group (Ferrer et al., 2003) (see Table 3, Figure 9) .
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Acute Cardiogenic Pulmonary Edema
One of the RCTs that included 89 patients showed statistically significant
improvements in the first 48-hour mortality, the need for intubation, and in the serious
complications in elderly patients ≥ 75 years of age admitted to the ED with ACPE and
treated with CPAP as compared to another group treated with the UMC (L’Her et al.,
2004; Figure 10). However, in contrast to most of the trials that were conducted on
ACPE, a larger RCT, which had 1069 patients from various medical centers in the UK,
despite showing that the NIV improved dyspnea and arterial blood gases (ABG) in one
hour, there were no statistically significant differences between the NIV group and the
UMC group, in rate of intubation and in one-week mortality rate (Gray et al., 2008) (see
Table 3, Figure 10). A large randomized patient study, (which included 130 patients)
from multiple EDs in Italy showed that there were improvements only in PaO2/FiO2
ratios, but showed a reduction in hypercapnic patients and not the other patients with
PaCO2 ≤ 45, which agreed with Gray’s conclusion (Nava et al., 2003). On the other
hand, Potts in his meta-analysis indicated that there is strong evidence of the efficacy of
NIV in the treatment of ACPE (Potts, 2009).

Post-Surgical AHRF
Two RCTs were conducted on post-lung resection (Auriant et al., 2001), and the
second assessed the efficacy of NIV to treat AHRF in patients who underwent major
abdominal surgery (Squadrone et al., 2005). Both studies showed statistically significant
differences in the rate of intubation. NIV successfully treats atelectasis (collapsed lung
units), which is very common in post-abdominal surgery. In the post-lung resection

35
study, the benefit of NIV is probably because of the presence of ACPE, which usually
responds well to NIV therapy. Aurient et al. did not assess complications, which showed
a significant decrease in Squadrone et al. However, there was a significant reduction in
mortality rate in the post-lung resection surgery population, yet there was no statistically
significant improvement in post-abdominal surgery when treated with the NIV as
compared to the UMC (see Table 3, Figure 11). The noticeable improvements in the
post-abdominal surgery could be because those elective cases were not considered a high
risk population.
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Table 3.
Efficacy of NIV+ UMC versus UMC Alone in This Review:
Study, year
(No. of
Participants)

1-Wysocki et
al.,1995 (n=41)

2- Confalonieri
et al., 1999
(n=56)

Disease

ARF (no
COPD)
PaCO2>45 (n=17)
PaCO2≤45 (n=24)
CAP+ARF
(n=23),
AHRF (n=33)*

ETI
&
MV
(%)
UMC
vs.
NIV
•

ICU
LOS
(days)
UMC
vs.
NIV

Hosp.
LOS
(days)
UMC
vs.
NIV

Complications Mortality
UMC vs. NIV

UMC vs.
NIV

•

NR

NR

•

•

•

•

•

•

3- Antonelli et
al., 2000.
(n=40)

ARF solid organ
transplantation

↓

↓

NR

↓

↓ICU

4- Delclaux et
al., 2000.
(n=123)

ALI/ARDS

•

•

•

↑

•

5-Auriant et al., AHRF post-lung
2001. (n=48)
resection

↓

•

•

NR

↓

6-Hilbert et al.,
2001. (n=52)
7-Keenan et al.,
2002. (n=81).

↓

↓

NR

↓

↓

•

•

•

•

•

AHRFimmunosuppressed
ARF, AHRF
postextubation

Table continues
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Table 3 (continued)
Study, year
(No. of
Participants)

10-Squadrone
et al.,
2005. (n=209)
11-Gray et al.,
2008. (n=1069

Disease

AHRF Postoperative
ACPE

ETI
&
MV
(%)
UMC
vs.
NIV
↓

•

ICU
LOS
(days)
UMC
vs.
NIV

Hosp.
LOS
(days)
UMC
vs.
NIV

Complications Mortality
UMC vs. NIV

UMC vs.
NIV

•

•

↓

•

NR

•

•

•

ETI & MV: endotracheal intubation and mechanical ventilation; ICU: intensive care unit;
LOS: length of stay; UMC: usual medical care; NIV: noninvasive ventilation; ARF: acute
respiratory failure; CAP: cardiogenic pulmonary edema; AHRF: acute hypoxemic
respiratory failure; ALI: acute lung injury; ARDS: acute respiratory distress syndrome;
ACPE: acute cardiogenic pulmonary edema; •: no significant change; ↓: significant
decrease after the use NIV; ↑: increase after the use NIV; NR: not recorded.
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Antonelli et al., 2000

80
70
60
50
40
30
20
10
0
Intubation

Complications
UMC

Mortality

NIV

Hilbert et al., 2001
100
80
60
40
20
0
Intubation

Complications
UMC

Mortality

NIV

Figure 6. Summary of the subgroup studies of patients with immunosupression who
treated NIV or UMC, which showed a statistically significant decrease in intubation,
complication, and mortality rate (p = 0.02, p=0.03, & p=0.05) respectively, and (p=0.03,
p= 0.02 & p=0.02) respectively.
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Declaux at al., 2000
50
40
30
20
10
0
Intubation

Complications
UMC

Mortality

NIV

Figure 7. Summary of the subgroup study of patient populations with ALI/ARDS who
were treated with NIV or just UMC showing no statistically significant improvement
with worse complications in the NIV group.

Keenan et al., 2002
80
70
60
50
40
30
20
10
0
Intubation

Complications
UMC

Mortality

NIV

Figure 8. Results of the study of patients with developed AHRF post-extubation and
either received NIV or just UMC showing no benefits from the use of NIV in this
patients’ group.

40

Confalonieri et al., 1999
50
40
30
20
10
0
Intubation

Mortality
UMC

NIV

Ferrer et al., 2003
60
50
40
30
20
10
0
Intubation

Mortality
UMC

NIV

Figure 9. Studies that assessed the effect of NIV as compared to UMC in patients with
community-acquired pneumonia who did not have underlying COPD disease.
Confalonieri et al. did not show a significant improvement in intubation nor in mortality
rates after using NIV, unlike Ferrer at al., which showed a statistically significant
improvement in intubation rate (p= 0.01) and mortality rate (p = 0.028).
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L'Her et al., 2004
40
35
30
25
20
15
10
5
0
Intubation

Complications
UMC

Mortality

NIV

Gray et al., 2008
50
40
30
20
10
0
Intubation

Complications
UMC

Mortality

NIV

Figure 10. Two studies that assess the efficacy of NIV versus UMC on acute cardiogenic
pulmonary edema (ACPE). L’Her et al. showed a significant improvement in both
intubation rate (p = 0.01) and complications rate (P = 0.002), but did not show a
significant drop in the mortality rate in elderly patients with ACPE. Gray et al., which
involved a larger study sample, didn’t show a significant improvement in intubation,
complications, or mortality rate.
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Auriant et al., 2001
60
50
40
30
20
10
0
Intubation

Mortality
UMC

NIV

Squadrone et al., 2005
12
10
8
6
4
2
0
Intubation

Mortality
UMC

NIV

Figure 11. Results of the subgroup in two studies of patients presented post-lung
resection AHRF(Auriant et al.), and post-elective abdominal surgery with AHRF, who
were treated with NIV versus UMC, showed a statistically significant improvement in
intubation rates (p=0.03, p=0.05). Both also showed a drop in mortality rates. In addition,
Squadrone et al. showed a statistically significant improvement in the complications rate
(P=0.0.2), which was not recorded in Aurient et al.
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CHAPTER VI: CONCLUSION
In the last few years, several randomized and non-randomized trials showed
strong evidence of the benefit of using NIV therapy in COPD exacerbation cases. This
researcher reviewed the literature to assess the efficacy of NIV in patients with acute
hypoxemic respiratory failure (AHRF).
From the analysis of the eleven RCTs that were included in this systematic
review, the overall results suggest that the use of NIV in AHRF patients decreases the
need for endotracheal intubation, ICU length of stay, and mortality rate. However, it is
difficult to generalize these results on most of the AHRF cases due to the wide
heterogeneity in the populations of these RCTs and due to small sample sizes in some of
the trials. Some subgroups showed clear benefits from the use of NIV as compared to the
UMC alone. This was seen in patients with immunosuppression after lung resection, and
in patients who underwent abdominal surgery, although the study involved only elective
procedures. Nevertheless, there was strong evidence of a significant benefit from the use
of NIV in reducing the death rate in ACPE, regardless of the RCT in Gray’s et al. In other
etiologies, the use of NIV showed various results.
More focused studies that concentrate on patient groups with AHRF, with less
heterogeneity in etiology would likely be more reliable. It is noteworthy that increased
clinical experience with the application, patient tolerance, and selection of the most
appropriate interface is fundamentally important (Kallet, 2009). Additionally, patient
monitoring has an important role in improving the outcomes.
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The use of NIV should not be a reason to delay endotracheal intubation when it is
indicated. Competent personnel such as respiratory therapists and registered nurses in
highly monitored clinical settings are always a critical factor for optimal use of NIV and
to ensure patient safety.
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